Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy

Lubberts, Sjoukje; Boer, Hink; Altena, Renske; Meijer, Coby; Roon, Arie M. van; Zwart, Nynke; Oosting, Sjoukje F.; Kamphuisen, Pieter Willem; Nuver, Janine; Smit, Andries J.; Mulder, André B.; Lefrandt, Joop D.; Gietema, Jourik A.

doi:10.1016/j.ejca.2016.05.022

Cited by 26 publications

(24 citation statements)

References 27 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case 1 and 3 had predisposing factors for venous and arterial TE events, respectively. 20 Although we are fully aware that the TE events in the intervention arm might have been a play of chance, we find it hard to ignore that the HIIT might have contributed to the unexpected high number of TE events. Proposed mechanisms for possible interactions between CBCT and high-intensity aerobic exercise that can potentiate the risk of TE events are described after a review of the literature.…”

Section: Discussionmentioning

confidence: 95%

“…The majority of studies were retrospective, apart from two studies with a prospective design, 20,21 and one where the design was not reported. 22 The studies were heterogeneous and study populations were often poorly described.…”

Section: T a B L Ementioning

confidence: 99%

“…During CBCT, 14 studies reported on incidence rates of venous TE events, ranging from 2% to 24% (Table 3). [20][21][22][23][24][25][26][27][28][29][30][31][32][33] The reported rates of venous TE events presented in Table 3 consists of deep vein thrombosis and pulmonary embolism, except for one study 26 which also includes superficial vein thrombosis. The reported incidence rate of pulmonary embolism ranged from 0% to 11%.…”

Section: T a B L Ementioning

confidence: 99%

“…The reported incidence rate of pulmonary embolism ranged from 0% to 11%. [20][21][22][23][24][26][27][28][29][30][31][32][33] Nine studies reported on the incidence rate of myocardial infarction ranging from 0% to 4%. [20][21][22][23]27,28,[32][33][34] Eight studies reported on the incidence rate of both pulmonary embolism or myocardial infarction, ranging from 0% to 15%.…”

Section: T a B L Ementioning

confidence: 99%

See 3 more Smart Citations

Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: Case reports and review of the literature

Thorsen

Haugnes

Fosså

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

The randomized "Testicular cancer and Aerobic and Strength Training trial" (TASTtrial) aimed to evaluate the effect of high-intensity interval training (HIIT) on cardiorespiratory fitness during cisplatin-based chemotherapy (CBCT) for testicular cancer (TC). Here, we report on an unexpected high number of thromboembolic (TE) events among patients randomized to the intervention arm, and on a review of the literature on TE events in TC patients undergoing CBCT. Patients aged 18 to 60 years with a diagnosis of metastatic germ cell TC, planned for 3 to 4 CBCT cycles, were randomized to a 9 to 12 weeks exercise intervention, or to a single lifestyle counseling session. The exercise intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate. The study was Abbreviations: AEs, adverse events; (B)EP, (bleomycin) etoposide and cisplatin; CBCT, cisplatin-based chemotherapy; CPET, cardiopulmonary exercise test; CRF, cardiorespiratory fitness; CT, computed tomography; dRVVT, diluted Russell's viper venom test; DXA, dual-energy X-ray absorptiometry; HI(I)T, high-intensity (interval) training; HR, heart rate; RCT, randomized controlled trial; TAST, testicular cancer and aerobic-and strength training; TC, testicular cancer; TE, thromboembolic events.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: T a B L Ementioning

confidence: 99%

Section: T a B L Ementioning

confidence: 99%

Section: T a B L Ementioning

confidence: 99%

See 2 more Smart Citations

Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: Case reports and review of the literature

Thorsen

Haugnes

Fosså

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Limitations of the Khorana score include the presence of platinum and pyrimidine analogue therapy, where risk stratification was not sensitive enough in the early stages of tumors. Therefore, the initiative of a "vascular fingerprint," a risk calculation score, has been suggested to detect risk of adverse arterial events among patients with anti-tumor therapy (Table 2) [10,12,42]. Cisplatin treatment, type and stage of primary malignancy, age, presence of cardiovascular diseases, elevated LDH, retroperitoneal metastatic lymph nodes in germ cell tumors, and high Khorana score, but not pre-chemotherapy platelet number and BMI, are independent risk factors for DIVI [8].…”

Section: Risk Assessmentmentioning

confidence: 99%

Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment

et al. 2019

View full text Add to dashboard Cite

Vascular side effects of standard chemotherapeutic drugs and novel anti-tumor agents complicate treatment cycles, increase non-cancer-related mortality rates, and decrease the quality of life in cancer survivors. Arterial thromboembolic events (ATEE) are associated with most anti-cancer medications. Previous articles have reported a variety of vascular events including ST-segment elevation myocardial infarction as one of the most severe acute arterial attacks. Cardiologists should play an early role in identifying those at high risk for vascular complications and tailor anti-thrombotic therapies in keeping with thromboembolic and bleeding risks. Early preventive steps and individualized chemotherapy may decrease anti-tumor treatment-related vascular events. Here, we aim to provide an extensive review of anti-tumor drug-induced vascular injury (DIVI), pathomechanisms, and risk stratification underlining arterial events. We give a summary of clinical manifestations, treatment options, and possible preventive measures of DIVI. Additionally, the treatment of modifiable risk factors and tailored choice of chemotherapy must be considered in all oncology patients to prevent DIVI. We propose a complex tool for ATEE risk stratification which is warranted for early prediction leading to less frequent complications in cancer patients. Keywords Drug-induced vascular injury • Anti-cancer treatment • Thromboembolic events • Prevention • Risk stratification Abbreviations ATEE Arterial thromboembolic events BEP Bleomycin-etoposide-cisplatin CAD Coronary arterial diseases DIVI Drug-induced vascular injury PAD Peripheral arterial diseases TKI Tyrosine kinase inhibitors vWF von Willebrand factor

show abstract

Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries

Nestler

Huber²,

Laury

et al. 2018

World J Urol

View full text Add to dashboard Cite

show abstract

Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy

Cited by 26 publications

References 27 publications

Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: Case reports and review of the literature

Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: Case reports and review of the literature

Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment

Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries

Contact Info

Product

Resources

About